461 related articles for article (PubMed ID: 23979365)
21. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
Tagami T; Matsui H; Horiguchi H; Fushimi K; Yasunaga H
J Thromb Haemost; 2015 Jan; 13(1):31-40. PubMed ID: 25393713
[TBL] [Abstract][Full Text] [Related]
22. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies.
Kudo D; Goto T; Uchimido R; Hayakawa M; Yamakawa K; Abe T; Shiraishi A; Kushimoto S
Crit Care; 2021 Mar; 25(1):114. PubMed ID: 33741010
[TBL] [Abstract][Full Text] [Related]
23. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
[TBL] [Abstract][Full Text] [Related]
24. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
[TBL] [Abstract][Full Text] [Related]
25. [How to use AT concentrate or recombinant thrombomodulin for the patients with sepsis analyzed by laboratory markers].
Eguchi Y; Yoshida T; Okabe H
Rinsho Byori; 2011 Feb; Suppl 147():213-5. PubMed ID: 21761775
[No Abstract] [Full Text] [Related]
26. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
Bernard GR; Ely EW; Wright TJ; Fraiz J; Stasek JE; Russell JA; Mayers I; Rosenfeld BA; Morris PE; Yan SB; Helterbrand JD
Crit Care Med; 2001 Nov; 29(11):2051-9. PubMed ID: 11700394
[TBL] [Abstract][Full Text] [Related]
27. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
Papageorgiou C; Jourdi G; Adjambri E; Walborn A; Patel P; Fareed J; Elalamy I; Hoppensteadt D; Gerotziafas GT
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):8S-28S. PubMed ID: 30296833
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction.
Hayakawa M; Kushimoto S; Watanabe E; Goto K; Suzuki Y; Kotani T; Kiguchi T; Yatabe T; Tagawa J; Komatsu F; Gando S
Thromb Haemost; 2017 May; 117(5):851-859. PubMed ID: 28229162
[TBL] [Abstract][Full Text] [Related]
29. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient.
Morino K; Honma Y; Kumei S; Watanabe T; Kume K; Yoshikawa I; Harada M
Intern Med; 2018 Nov; 57(21):3079-3085. PubMed ID: 29877275
[TBL] [Abstract][Full Text] [Related]
31. Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis.
Yamakawa K; Murao S; Aihara M
Thromb Haemost; 2019 Jan; 119(1):56-65. PubMed ID: 30597500
[TBL] [Abstract][Full Text] [Related]
32. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M
J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023
[TBL] [Abstract][Full Text] [Related]
33. Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: relatively safe and possibly effective.
Fink MP
Crit Care Med; 2013 Sep; 41(9):2221-3. PubMed ID: 23979366
[No Abstract] [Full Text] [Related]
34. Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.
Okuda A; Ogura T; Imanishi M; Miyano A; Nishioka N; Higuchi K
Gut Liver; 2018 Jul; 12(4):471-477. PubMed ID: 29699063
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T
J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial.
Sun Y; Ding R; Sun H; Liang Y; Ma X
Trials; 2024 Jan; 25(1):4. PubMed ID: 38167115
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.
Ogawa Y; Yamakawa K; Ogura H; Kiguchi T; Mohri T; Nakamori Y; Kuwagata Y; Shimazu T; Hamasaki T; Fujimi S
J Trauma Acute Care Surg; 2012 May; 72(5):1150-7. PubMed ID: 22673239
[TBL] [Abstract][Full Text] [Related]
38. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
[TBL] [Abstract][Full Text] [Related]
39. Bleeding events associated with recombinant human soluble thrombomodulin, classified according to renal function, in sepsis-induced disseminated intravascular coagulation.
Onoda T; Aoyama K; Suzuki M; Matsumoto T; Tanaka H; Ishii T
Int J Clin Pharmacol Ther; 2023 Jul; 61(7):297-305. PubMed ID: 37114512
[TBL] [Abstract][Full Text] [Related]
40. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
